Adiponectin (ADPN), also known as apM1, Acrp30, GBP28 and adipoQ, is a circulating hormone predominantly produced from adipose tissue (fat). Many pharmacological studies demonstrated that this protein possesses potent anti-diabetic, anti-atherogenic and anti-inflammatory functions. Supplementation of adiponectin protein can decrease blood glucose, improve insulin sensitivity, alleviate fatty liver and prevent atherosclerosis1. Decreased circulating levels of plasma adiponectin (hypoadiponectinaemia) are associated with increased body mass index (BMI), and decreased insulin sensitivity. A large number of longitudinal studies in different ethnic groups uniformly demonstrated that circulating adiponectin levels are decreased significantly in type 2 diabetes (T2D) and related complications and low circulating adiponectin levels indicate the increased risk for the development of T2D2. It is generally accepted that the higher the level of adiponectin, the lower the risk of developing diabetes. The level less than 4 mg/L in female or less than 3.5 mg/L in male indicates significant increased risk of developing diabetes.

Adiponectin PETIA kit developed by IMD takes advantage of its patented proprietary recombinant antigen and antibodies, and can accurately measure adiponectin in serum/plasma using any automatic chemical analyser.

This assay is a turbidimetric immunoassay for the quantitative measurement of adiponectin in human serum and plasma. A standard or sample is added into a cuvette and mixed with the reaction buffer R1. After a short incubation, the test reagent R2, which is a suspension of microparticles coated with an antibody highly specific to adiponectin, is added into the cuvette and mixed. The presence of adiponectin in the standard or sample causes the immune-particles to aggregate. The extent to which the microparticles aggregate is quantified by the amount of light scattering measured as absorbance by a chemistry analyzer. The concentration of adiponectin in unknown samples can be interpolated from a reference curve using the standards provided.

TYPICAL STANDARD CURVE

ADPN (mg/L)	Absorbance (570 nm)
0	-0.0099
2	0.0264
5	0.0882
10	0.1872
20	0.3359
40	0.4906

Assay procedures may vary depending on the automated chemistry analyzer to be used. A general example of assay procedures is stated as follow:

1. Dispense 150µl of R1 into a clean cuvette

2. Add 1.5µl of serum or plasma sample or adiponectin calibrator and incubate at 37˚C for 5 minutes

3. Further add 50µl of R2

4. Read change of absorbance at 570 nm for 8 minutes after the addition of R2

5. Calculate the concentration of Adiponectin in unknown sample by interpolation from a reference curve using the standards provided

Cat. No.	Size	Approximately tests
51010-05	R1: 15ml, R2: 5ml	100
51010-10	R1: 30ml, R2: 10ml	200
51010-20	R1: 60ml, R2: 20ml	400
51010-50	R1: 150ml, R2: 50ml	1000
51010-100	R1: 300ml, R2: 100ml	2000

For bulk order, please enquire

Product	Catalog           Number	Format	Method
Calibrator	51010-S1	5 x 1ml
Control	51010-C1	2 x 1ml

1. Liu D, Wu L, Gao Q, Long X, Hou X, Qian L, Ni J, Fang Q, Li H, Jia W. FGF21/adiponectin ratio predicts deterioration in glycemia: a 4.6-year prospective study in China. Cardiovascular diabetology. 2021 Dec;20(1):1-1.
2. Bishay RH, Tonks KT, George J, Samocha-Bonet D, Meyerowitz-Katz G, Chisholm DJ, James DE, Greenfield JR. Plasma Bile Acids More Closely Align With Insulin Resistance, Visceral and Hepatic Adiposity Than Total Adiposity. J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1131-e1139.
3. Ye X, Yu R, Jiang F, Hou X, Wei L, Bao Y, Jia W. Osteocalcin and Risks of Incident Diabetes and Diabetic Kidney Disease: A 4.6-Year Prospective Cohort Study. Diabetes Care. 2022 Apr 1;45(4):830-836. doi: 10.2337/dc21-2113.
4. Feng JN, Shao W, Jin T. Short-term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice. Physiol Rep. 2023 Mar;11(5):e15620. doi: 10.14814/phy2.15620.
5. Wang Y, Yu H, Ma X, Wang Y, Liu W, Zhang H, Chen W, Yu S, Bao Y, Yang Y. Clusterin is closely associated with adipose tissue insulin resistance. Diabetes Metab Res Rev. 2023 Jul 6:e3688.